rabaptin, RAB GTPase binding effector protein 1Genealiases: RAB5EP · RABPT5
Q-omics provides the consensus-scored RABEP1 profile across patient tissues and cancer cell-line models. RABEP1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, RABEP1 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, RABEP1 protein abundance shows 28,339 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight MESO, HNSC, and BRCA as cancer lineages where RABEP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RABEP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RABEP1 survival associations across molecular data types. RABEP1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RABEP1 RNA expression–survival associations across cancer types. High RABEP1 expression shows unfavorable associations in MESO, KICH and UVM, but favorable associations in KIRC, BRCA and SCLC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify MESO as the clearest survival context for RABEP1 RNA expression.
This table summarizes RABEP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for RABEP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RABEP1 shows lower tumor expression in BLCA, THCA, LUAD and KICH and higher tumor expression in HNSC and CHOL. The HNSC box plot shows higher RABEP1 RNA expression in tumor versus normal tissue (log2 FC = +0.759, t-test p < 0.001).
This table shows molecular features associated with RABEP1 in patient tissues and cancer cell lines. In patient samples, RABEP1 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, RABEP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and LARGE_INTESTINE.
